// App-Quantinova.ai

10508 : Plasma asparaginase activity and asparagine depletion in patients with acute lymphoblastic leukemia (ALL) treated with pegaspargase (SS-PEG E. coli L-asparaginase): Results from Childrens Oncology Group (COG) study AALL07P4.

Researchers

Presenter

  • Reuven J. Schore

Principal Investigators

  • Meenakshi Devidas

  • Archie Bleyer

  • Gregory H. Reaman

  • Naomi J. Winick

  • Mignon L. Loh

  • Elizabeth A. Raetz

  • William L. Carroll

  • Stephen Hunger

  • Anne L. Angiolillo

Medical Centers

  • Children's Natl Medcl Ctr, Washington, DC

  • University of Florida, Cainsvillle, FL

  • St. Charles Medical Center, Bend, OR

  • U.S. Food and Drug Administration, Silver Spring, MD

  • The University of Texas Southwestern Medical Center, Dallas, TX

  • UC San Francisco, San Francisco, CA

  • University of Utah, Salt Lake City, UT

  • NYU Langone Medical Center, New York, NY

  • Childrens Hospital of Philadelphia, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Pegaspargase

  • Oncaspar

  • Asparaginase

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • NCT00671034

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved